Dublin, Nov. 03, 2021 (GLOBE NEWSWIRE) -- The "Targeted Oncology Therapeutics: Hematology Cancers" report has been added to ResearchAndMarkets.com's offering.
There is a strong trend in oncology toward therapeutics that focus on specific targeting mechanisms to achieve positive outcomes.
The success of CAR-T technology for the treatment of haematology cancers has been a glowing example of the power of molecular manipulation to treat specific conditions.
More than three dozen targeted treatments, using novel pathways and signalling, have achieved results that represent a new era in oncology and antineoplastic therapeutics. These approaches have attracted a growing number of drug developers anxious to profit from therapies that can ease the physical, psychological, and emotional burden of cancer. Efforts to re-focus and apply this technology to solid tumours is now aggressively being pursued by a growing list of market participants. This report examines leading mAb and kinase inhibitor therapeutic drugs and the biomarkers they utilize.
Target Oncology Haematology Cancers - What You Will Learn
- What is the market share of approved haematology cancer therapeutics?
- What is the global supply picture for targeted haematology cancer therapeutics?
- Who are the market leaders, by Indication? by Product?
- What is the therapeutic coverage across all oncology indications? What are the product opportunities?
- What are the established products in this space? by target, indication, API class, revenue?
- What is the competitive picture for the haematology cancer market segments?
- Drug treatment resources
- Competitive therapy map
- Clinical trial activity
- Who are the leading competitors in the field of next-generation haematology cancer therapeutics?
Key Topics Covered:
- Executive Summary
- Targeted Oncology Therapeutics
- Hematology Cancers
- Executive Summary
- The Recombinant Drug Ecosystem
- mAbs and Targeted Oncology Therapeutics
- Leukemias
- Acute Lymphocytic Leukemia
- Chronic Lymphocytic Leukemia
- Childhood Acute Lymphoblastic Leukemia
- Acute Myeloid Leukemia
- Chronic Myelogenous Leukemia
- Lymphomas
- Hodgkin Lymphoma
- Non-Hodgkin's Lymphoma
- Multiple Myeloma
- Biological Drugs for Hematology Cancers
- Monoclonal Antibodies (Twelve Therapeutic Products)
- Tyrosine Kinase Inhibitors
- ALL with Philadelphia chromosome (Ph+ ALL)
- FDA Approved TKIs (Six Therapeutic Products)
- Chimeric Antigen Receptor-T (CAR-T) (Five Products)
- The Therapeutic Market Landscape
- Diagnostic Tools
- Drugs in Development - The Clinical Trial Picture
- Leukemias
- Lymphomas
- Myeloma
- FDA-Approved Targeted Oncology
- Therapeutics for Hematology Cancers
Companies Mentioned
- Amgen
- Astellas
- AstraZeneca
- Bristol-Myers Squibb
- Celltrion
- Daiichi Sankyo
- Eli Lilly
- Genentech
- Genzyme
- GlaxoSmithKline
- Janssen Biotech
- Kyowa Kirin
- Merck Sharp & Dohme
- Mylan GmbH
- Pfizer
- Regeneron Pharmaceuticals
- Samsung Bioepis
- Spetrum Pharmaceuticals
- United Therapeutics
- Roche
- EMD Serono
- Immunex
- Lonza Biologics
- Lonza AG
- Seattle Genetics
- Biogen
For more information about this report visit https://www.researchandmarkets.com/r/6uxb44